Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LEDIZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Crown Ether ADC 4d
|
|||||
| Synonyms |
Crown-Ether-ADC-4d
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Anaplastic large cell lymphoma [ICD11:2A90]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Brentuximab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
3-Amino-alpha-cyclodextrin-Val-Cit-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 16.00 pM | Positive CD30 expression (CD30+++/++) | ||
| Method Description |
Cells were incubated for 24 h at 37°C with 5% CO2. The cells were treated by addition of ADCs 4a-f, 5a-b and 6a-b, dilution series (50 uL/well) and were then incubated at 37°C/5% CO2 for a further 96 h. Cell viability assays were carried out using CellTiter-Glo Luminescent reagent as per the manufacturers instructions.
|
||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.